{"id":379483,"date":"2020-11-12T07:33:37","date_gmt":"2020-11-12T12:33:37","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=379483"},"modified":"2020-11-12T07:33:37","modified_gmt":"2020-11-12T12:33:37","slug":"crescita-reports-third-quarter-2020-results","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/crescita-reports-third-quarter-2020-results\/","title":{"rendered":"Crescita Reports Third Quarter 2020 Results"},"content":{"rendered":"<div class=\"xn-newslines\">\n<p class=\"xn-distributor\">PR Newswire<\/p>\n<\/p><\/div>\n<div class=\"xn-content\">\n<p class=\"prntac\">\n        <b>Strong Ending Cash Balance of <span class=\"xn-money\">$13.9M<\/span><\/b>\n      <\/p>\n<div class=\"PRN_ImbeddedAssetReference\" id=\"DivAssetPlaceHolder1\">\n<p>\n          <a href=\"https:\/\/mma.prnewswire.com\/media\/1332930\/Crescita_Therapeutics_Inc__Crescita_Reports_Third_Quarter_2020_R.html\" target=\"_blank\" rel=\"nofollow noopener noreferrer\"><br \/>\n            <img decoding=\"async\" src=\"https:\/\/mma.prnewswire.com\/media\/1332930\/Crescita_Therapeutics_Inc__Crescita_Reports_Third_Quarter_2020_R.jpg\" title=\"Crescita Therapeutics Inc. Logo (CNW Group\/Crescita Therapeutics Inc.)\" alt=\"Crescita Therapeutics Inc. Logo (CNW Group\/Crescita Therapeutics Inc.)\" \/><br \/>\n          <\/a>\n        <\/p>\n<\/p><\/div>\n<p>\n        <span class=\"xn-location\">LAVAL, QC<\/span>, <span class=\"xn-chron\">Nov. 12, 2020<\/span> \/CNW Telbec\/ Crescita Therapeutics Inc. (TSX: CTX) (OTC US: CRRTF) (&#8220;Crescita&#8221; or the &#8220;Company&#8221;), a growth-oriented, innovation-driven Canadian commercial dermatology company with in-house research &amp; development (&#8220;R&amp;D&#8221;) and manufacturing capabilities,\u00a0today reported its financial results for the third quarter ended <span class=\"xn-chron\">September 30, 2020<\/span> (&#8220;Q3-F2020&#8221;). <i>\u00a0<\/i>All amounts presented are in thousands of Canadian dollars (&#8220;CAD&#8221;) unless otherwise noted.<\/p>\n<p>\n        <b>Financial Highlights<\/b><br \/>\n        <b>\u00a0\u2013 Q3-F2020 vs. Q3-F2019 <\/b>\n      <\/p>\n<ul type=\"disc\">\n<li>Revenue was <span class=\"xn-money\">$7,301<\/span> compared to <span class=\"xn-money\">$4,906<\/span>, an increase of <span class=\"xn-money\">$2,395<\/span>; <\/li>\n<li>In Q3-F2020, the Company amended its licensing agreement with commercial partner Taro Pharmaceuticals Inc. (&#8220;Taro&#8221;) for Pliaglis<sup>\u00ae<\/sup> in the U.S. and received a total of <span class=\"xn-money\">$5,151<\/span><span class=\"xn-money\">(US$3,855)<\/span>. Revenue was recorded as follows: <\/li>\n<ul type=\"circle\">\n<li>\n            <span class=\"xn-money\">$4,483<\/span><br \/>\n            <span class=\"xn-money\">(US$3,355)<\/span> as licensing revenue (See <i>Revenue and Q3-F2020 Corporate Developments<\/i>); <\/li>\n<li>\n            <span class=\"xn-money\">$668<\/span><br \/>\n            <span class=\"xn-money\">(US$500)<\/span> as Other Income (See <i>Other Income \u2013 Taro Amendment<\/i>);<\/li>\n<\/ul>\n<li>Gross profit was <span class=\"xn-money\">$6,129<\/span> representing an increase of <span class=\"xn-money\">$2,686<\/span>; <\/li>\n<li>Operating expenses (excluding COGS) were <span class=\"xn-money\">$2,259<\/span>, compared to <span class=\"xn-money\">$2,965<\/span>, a decrease of <span class=\"xn-money\">$706<\/span>; <\/li>\n<li>Adjusted EBITDA was <span class=\"xn-money\">$4,316<\/span> compared to <span class=\"xn-money\">$939<\/span>, an increase of <span class=\"xn-money\">$3,377<\/span>; <\/li>\n<li>Ending cash position was <span class=\"xn-money\">$13,856<\/span>, an increase of <span class=\"xn-money\">$851<\/span> year-over-year and <span class=\"xn-money\">$4,591<\/span> versus Q2-F2020. <\/li>\n<\/ul>\n<p \/>\n<p>&#8220;We delivered a strong quarter with a record-high cash balance since Q1-F2016, as we continue to focus on finding commercial partners for Pliaglis. Over the last few months, we have advanced licensing opportunities for Pliaglis in the rest of world, most recently signing agreements in <span class=\"xn-location\">Austria<\/span>, <span class=\"xn-location\">Mexico<\/span>, and perhaps the most meaningful for our future, <span class=\"xn-location\">China<\/span>,&#8221; commented <span class=\"xn-person\">Serge Verreault<\/span>, President and Chief Executive Officer of Crescita. &#8220;Sales in our Commercial Skincare segment posted a modest increase versus the prior year, reflecting the reopening of the economy in the summer months and showed an encouraging trend as we headed into the second wave of the pandemic. We are cautiously optimistic but cannot discount the impact that any other government-mandated closures may have in the coming months.&#8221;<\/p>\n<p>&#8220;Our goal remains to secure recurring revenue streams for the future, and we are evaluating ways to best deploy our cash on hand, including strategic investments to grow our Company. On a separate note, I would like to thank our employees for their exceptional work during this difficult time and our clients for their trust and loyalty,&#8221; added Mr. Verreault.\u00a0<\/p>\n<p>\n        <b>Q3-F2020 Corporate Developments<\/b>\n      <\/p>\n<ul type=\"disc\">\n<li>\n          <b>Patent Granted for Enhanced Formulation of Pliaglis<br \/><\/b>On <span class=\"xn-chron\">August 25, 2020<\/span>, the Company was granted U.S. Patent No. 10,751,305 for Solid-Forming Topical Formulations for Pain Control by the United States Patent and Trademark Office which covers an enhanced formulation of Pliaglis through <span class=\"xn-chron\">January 14, 2031<\/span>. <\/li>\n<li>\n          <b>Licensing Agreement for Pliaglis in <span class=\"xn-location\">Austria<\/span><br \/><\/b>On <span class=\"xn-chron\">August 12, 2020<\/span>, the Company entered into a commercialization license agreement with Pelpharma, a privately held Austrian pharmaceutical company specializing in the treatment of various skin and nail diseases, granting them the exclusive rights to sell and distribute Pliaglis in <span class=\"xn-location\">Austria<\/span>. <\/li>\n<li>\n          <b>Amendment to Development and Commercialization Agreement with Taro<br \/><\/b>On <span class=\"xn-chron\">July 28, 2020<\/span>, the Company announced that it entered into an amendment to the development and commercialization agreement with Taro (the &#8220;Taro Amendment&#8221;) with regard to Pliaglis in the U.S. The Taro Amendment entitled the Company to receive a one-time payment in the aggregate amount of <span class=\"xn-money\">$5,151<\/span><span class=\"xn-money\">(US$3,855)<\/span>. <\/li>\n<\/ul>\n<p \/>\n<p>\n        <b>Subsequent Events<\/b>\n      <\/p>\n<ul type=\"disc\">\n<li>\n          <b>Licensing Agreement for Pliaglis in <span class=\"xn-location\">China<\/span><br \/><\/b>On <span class=\"xn-chron\">November 5, 2020<\/span>, the Company announced that it entered into an exclusive agreement with Juyou-Biotechnology Co. Ltd (&#8220;Juyou&#8221;), a biotechnology company that develops and sells medical and cosmetic skin care products, for the commercialization and development of Pliaglis<sup>\u00ae<\/sup> and an enhanced formulation of Pliaglis in mainland <span class=\"xn-location\">China<\/span>. <\/li>\n<li>\n          <b>Licensing Agreement for Pliaglis in <span class=\"xn-location\">Mexico<\/span><br \/><\/b>On <span class=\"xn-chron\">October 19, 2020<\/span>, the Company entered into a commercialization and license agreement with LIV LABORAT\u00d3RIOS (&#8220;LIV&#8221;), a division of MINOS Labs, a privately held Mexican group of pharmaceutical, consulting, and regulatory companies. LIV specializes in dermatology solutions and sells directly to physicians. The agreement grants LIV the exclusive rights to distribute and sell Pliaglis in <span class=\"xn-location\">Mexico<\/span>. <\/li>\n<\/ul>\n<p \/>\n<p>\n        <b>Q3-F2020 Financial Results<\/b><br \/>\n        <b>\u00a0<\/b>\n      <\/p>\n<p>\n        <b><br \/>\n          <i>Note:<\/i><br \/>\n        <\/b><br \/>\n        <i>\u00a0The Management&#8217;s Discussion and Analysis (&#8220;MD&amp;A&#8221;), Condensed Consolidated Interim Financial Statements and accompanying notes for the three and nine months ended <span class=\"xn-chron\">September 30, 2020<\/span> can be found at <a target=\"_blank\" href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=2979578-1&amp;h=3731066294&amp;u=http%3A%2F%2Fwww.crescitatherapeutics.com%2Finvestors%2F&amp;a=www.crescitatherapeutics.com%2Finvestors\" rel=\"nofollow noopener noreferrer\">www.crescitatherapeutics.com\/investors<\/a> and have been filed on SEDAR at <a target=\"_blank\" href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=2979578-1&amp;h=4089425197&amp;u=http%3A%2F%2Fwww.sedar.com%2F&amp;a=www.sedar.com\" rel=\"nofollow noopener noreferrer\">www.sedar.com<\/a>.<\/i>\n      <\/p>\n<p>\n        <b>Summary Financial Results<\/b><br \/>\n        <b>\u00a0<\/b>\n      <\/p>\n<div>\n<table cellspacing=\"0\" cellpadding=\"0\" border=\"0\" class=\"prntblns\">\n<tr>\n<td class=\"prngen2\">\n              \n            <\/td>\n<td colspan=\"7\" class=\"prngen3\">\n<p class=\"prnews_p\">\n                <span class=\"prnews_span\"><br \/>\n                  <b>Three months ended <br \/>September 30,<\/b><br \/>\n                <\/span>\n              <\/p>\n<\/td>\n<td class=\"prngen2\">\n              \n            <\/td>\n<td colspan=\"6\" class=\"prngen3\">\n<p class=\"prnews_p\">\n                <span class=\"prnews_span\"><br \/>\n                  <b>Nine months ended\u00a0 <br \/>September 30,<\/b><br \/>\n                <\/span>\n              <\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"prngen4\">\n<p class=\"prnews_p\">\n                <span class=\"prnews_span\"><br \/>\n                  <i>In 000&#8217;s of CAD except earnings per share and number of shares<\/i><br \/>\n                <\/span>\n              <\/p>\n<\/td>\n<td colspan=\"3\" class=\"prngen5\">\n<p class=\"prnews_p\">\n                <span class=\"prnews_span\"><br \/>\n                  <b>2020<\/b><br \/>\n                <\/span>\n              <\/p>\n<\/td>\n<td colspan=\"4\" class=\"prngen5\">\n<p class=\"prnews_p\">\n                <span class=\"prnews_span\">2019<\/span>\n              <\/p>\n<\/td>\n<td class=\"prngen6\">\n              \n            <\/td>\n<td colspan=\"3\" class=\"prngen5\">\n<p class=\"prnews_p\">\n                <span class=\"prnews_span\"><br \/>\n                  <b>2020<\/b><br \/>\n                <\/span>\n              <\/p>\n<\/td>\n<td colspan=\"3\" class=\"prngen5\">\n<p class=\"prnews_p\">\n                <span class=\"prnews_span\">2019<\/span>\n              <\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"prngen6\">\n              \n            <\/td>\n<td colspan=\"3\" class=\"prngen6\">\n<p class=\"prnews_p\">\n                <span class=\"prnews_span\"><br \/>\n                  <b>$<\/b><br \/>\n                <\/span>\n              <\/p>\n<\/td>\n<td colspan=\"4\" class=\"prngen6\">\n<p class=\"prnews_p\">\n                <span class=\"prnews_span\">$<\/span>\n              <\/p>\n<\/td>\n<td class=\"prngen6\">\n              \n            <\/td>\n<td colspan=\"3\" class=\"prngen6\">\n<p class=\"prnews_p\">\n                <span class=\"prnews_span\"><br \/>\n                  <b>$<\/b><br \/>\n                <\/span>\n              <\/p>\n<\/td>\n<td colspan=\"3\" class=\"prngen6\">\n<p class=\"prnews_p\">\n                <span class=\"prnews_span\">$<\/span>\n              <\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"prngen7\">\n<p class=\"prnews_p\">\n                <span class=\"prnews_span\">Commercial skincare<\/span>\n              <\/p>\n<\/td>\n<td colspan=\"3\" class=\"prngen6\">\n<p class=\"prnews_p\">\n                <span class=\"prnews_span\"><br \/>\n                  <b>1,782<\/b><br \/>\n                <\/span>\n              <\/p>\n<\/td>\n<td colspan=\"4\" class=\"prngen6\">\n<p class=\"prnews_p\">\n                <span class=\"prnews_span\">1,705<\/span>\n              <\/p>\n<\/td>\n<td class=\"prngen6\">\n              \n            <\/td>\n<td colspan=\"3\" class=\"prngen6\">\n<p class=\"prnews_p\">\n                <span class=\"prnews_span\"><br \/>\n                  <b>4,625<\/b><br \/>\n                <\/span>\n              <\/p>\n<\/td>\n<td colspan=\"3\" class=\"prngen6\">\n<p class=\"prnews_p\">\n                <span class=\"prnews_span\">5,390<\/span>\n              <\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"prngen7\">\n<p class=\"prnews_p\">\n                <span class=\"prnews_span\">Licensing and royalties<\/span>\n              <\/p>\n<\/td>\n<td colspan=\"3\" class=\"prngen6\">\n<p class=\"prnews_p\">\n                <span class=\"prnews_span\"><br \/>\n                  <b>4,999<\/b><br \/>\n                <\/span>\n              <\/p>\n<\/td>\n<td colspan=\"4\" class=\"prngen6\">\n<p class=\"prnews_p\">\n                <span class=\"prnews_span\">2,537<\/span>\n              <\/p>\n<\/td>\n<td class=\"prngen6\">\n              \n            <\/td>\n<td colspan=\"3\" class=\"prngen6\">\n<p class=\"prnews_p\">\n                <span class=\"prnews_span\"><br \/>\n                  <b>6,865<\/b><br \/>\n                <\/span>\n              <\/p>\n<\/td>\n<td colspan=\"3\" class=\"prngen6\">\n<p class=\"prnews_p\">\n                <span class=\"prnews_span\">11,037<\/span>\n              <\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"prngen4\">\n<p class=\"prnews_p\">\n                <span class=\"prnews_span\">Manufacturing and services<\/span>\n              <\/p>\n<\/td>\n<td colspan=\"3\" class=\"prngen6\">\n<p class=\"prnews_p\">\n                <span class=\"prnews_span\"><br \/>\n                  <b>520<\/b><br \/>\n                <\/span>\n              <\/p>\n<\/td>\n<td colspan=\"4\" class=\"prngen6\">\n<p class=\"prnews_p\">\n                <span class=\"prnews_span\">664<\/span>\n              <\/p>\n<\/td>\n<td class=\"prngen6\">\n              \n            <\/td>\n<td colspan=\"3\" class=\"prngen6\">\n<p class=\"prnews_p\">\n                <span class=\"prnews_span\"><br \/>\n                  <b>1,359<\/b><br \/>\n                <\/span>\n              <\/p>\n<\/td>\n<td colspan=\"3\" class=\"prngen6\">\n<p class=\"prnews_p\">\n                <span class=\"prnews_span\">2,090<\/span>\n              <\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"prngen4\">\n<p class=\"prnews_p\">\n                <span class=\"prnews_span\"><br \/>\n                  <b>Revenues<\/b><br \/>\n                <\/span>\n              <\/p>\n<\/td>\n<td colspan=\"3\" class=\"prngen8\">\n<p class=\"prnews_p\">\n                <span class=\"prnews_span\"><br \/>\n                  <b>7,301<\/b><br \/>\n                <\/span>\n              <\/p>\n<\/td>\n<td colspan=\"4\" class=\"prngen8\">\n<p class=\"prnews_p\">\n                <span class=\"prnews_span\">4,906<\/span>\n              <\/p>\n<\/td>\n<td class=\"prngen6\">\n              \n            <\/td>\n<td colspan=\"3\" class=\"prngen8\">\n<p class=\"prnews_p\">\n                <span class=\"prnews_span\"><br \/>\n                  <b>12,849<\/b><br \/>\n                <\/span>\n              <\/p>\n<\/td>\n<td colspan=\"3\" class=\"prngen8\">\n<p class=\"prnews_p\">\n                <span class=\"prnews_span\">18,517<\/span>\n              <\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"prngen7\">\n<p class=\"prnews_p\">\n                <span class=\"prnews_span\">Cost of goods sold<\/span>\n              <\/p>\n<\/td>\n<td colspan=\"3\" class=\"prngen6\">\n<p class=\"prnews_p\">\n                <span class=\"prnews_span\"><br \/>\n                  <b>1,172<\/b><br \/>\n                <\/span>\n              <\/p>\n<\/td>\n<td colspan=\"4\" class=\"prngen6\">\n<p class=\"prnews_p\">\n                <span class=\"prnews_span\">1,463<\/span>\n              <\/p>\n<\/td>\n<td class=\"prngen6\">\n              \n            <\/td>\n<td colspan=\"3\" class=\"prngen6\">\n<p class=\"prnews_p\">\n                <span class=\"prnews_span\"><br \/>\n                  <b>3,164<\/b><br \/>\n                <\/span>\n              <\/p>\n<\/td>\n<td colspan=\"3\" class=\"prngen6\">\n<p class=\"prnews_p\">\n                <span class=\"prnews_span\">4,113<\/span>\n              <\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"prngen7\">\n<p class=\"prnews_p\">\n                <span class=\"prnews_span\"><br \/>\n                  <b>Gross Profit<\/b><br \/>\n                <\/span>\n              <\/p>\n<\/td>\n<td colspan=\"3\" class=\"prngen6\">\n<p class=\"prnews_p\">\n                <span class=\"prnews_span\"><br \/>\n                  <b>6,129<\/b><br \/>\n                <\/span>\n              <\/p>\n<\/td>\n<td colspan=\"4\" class=\"prngen6\">\n<p class=\"prnews_p\">\n                <span class=\"prnews_span\">3,443<\/span>\n              <\/p>\n<\/td>\n<td class=\"prngen6\">\n              \n            <\/td>\n<td colspan=\"3\" class=\"prngen6\">\n<p class=\"prnews_p\">\n                <span class=\"prnews_span\"><br \/>\n                  <b>9,685<\/b><br \/>\n                <\/span>\n              <\/p>\n<\/td>\n<td colspan=\"3\" class=\"prngen6\">\n<p class=\"prnews_p\">\n                <span class=\"prnews_span\">14,404<\/span>\n              <\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"prnsbt1 prnsbr1 prnvab prnsbbd prnpl6 prnsbl1 prnpr6\">\n<p class=\"prnews_p\">\n                <span class=\"prnews_span\"><br \/>\n                  <i>Gross margin as a % of revenue<\/i><br \/>\n                <\/span>\n              <\/p>\n<\/td>\n<td colspan=\"3\" class=\"prngen10\">\n<p class=\"prnews_p\">\n                <span class=\"prnews_span\"><br \/>\n                  <i><br \/>\n                    <b>83.9%<\/b><br \/>\n                  <\/i><br \/>\n                <\/span>\n              <\/p>\n<\/td>\n<td colspan=\"4\" class=\"prngen10\">\n<p class=\"prnews_p\">\n                <span class=\"prnews_span\"><br \/>\n                  <i>70.2%<\/i><br \/>\n                <\/span>\n              <\/p>\n<\/td>\n<td class=\"prngen6\">\n              \n            <\/td>\n<td colspan=\"3\" class=\"prngen10\">\n<p class=\"prnews_p\">\n                <span class=\"prnews_span\"><br \/>\n                  <i><br \/>\n                    <b>75.4%<\/b><br \/>\n                  <\/i><br \/>\n                <\/span>\n              <\/p>\n<\/td>\n<td colspan=\"3\" class=\"prngen10\">\n<p class=\"prnews_p\">\n                <span class=\"prnews_span\"><br \/>\n                  <i>77.8%<\/i><br \/>\n                <\/span>\n              <\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"prngen6\">\n              \n            <\/td>\n<td colspan=\"3\" class=\"prngen6\">\n              \n            <\/td>\n<td colspan=\"4\" class=\"prngen6\">\n              \n            <\/td>\n<td class=\"prngen6\">\n              \n            <\/td>\n<td colspan=\"3\" class=\"prngen6\">\n              \n            <\/td>\n<td colspan=\"3\" class=\"prngen6\">\n              \n            <\/td>\n<\/tr>\n<tr>\n<td class=\"prngen7\">\n<p class=\"prnews_p\">\n                <span class=\"prnews_span\">Research &amp; development<\/span>\n              <\/p>\n<\/td>\n<td colspan=\"3\" class=\"prngen6\">\n<p class=\"prnews_p\">\n                <span class=\"prnews_span\"><br \/>\n                  <b>212<\/b><br \/>\n                <\/span>\n              <\/p>\n<\/td>\n<td colspan=\"4\" class=\"prngen6\">\n<p class=\"prnews_p\">\n                <span class=\"prnews_span\">462<\/span>\n              <\/p>\n<\/td>\n<td class=\"prngen6\">\n              \n            <\/td>\n<td colspan=\"3\" class=\"prngen6\">\n<p class=\"prnews_p\">\n                <span class=\"prnews_span\"><br \/>\n                  <b>776<\/b><br \/>\n                <\/span>\n              <\/p>\n<\/td>\n<td colspan=\"3\" class=\"prngen6\">\n<p class=\"prnews_p\">\n                <span class=\"prnews_span\">1,338<\/span>\n              <\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"prngen7\">\n<p class=\"prnews_p\">\n                <span class=\"prnews_span\">Selling, general &amp; administrative<\/span>\n              <\/p>\n<\/td>\n<td colspan=\"3\" class=\"prngen6\">\n<p class=\"prnews_p\">\n                <span class=\"prnews_span\"><br \/>\n                  <b>1,632<\/b><br \/>\n                <\/span>\n              <\/p>\n<\/td>\n<td colspan=\"4\" class=\"prngen6\">\n<p class=\"prnews_p\">\n                <span class=\"prnews_span\">2,092<\/span>\n              <\/p>\n<\/td>\n<td class=\"prngen6\">\n              \n            <\/td>\n<td colspan=\"3\" class=\"prngen6\">\n<p class=\"prnews_p\">\n                <span class=\"prnews_span\"><br \/>\n                  <b>5,383<\/b><br \/>\n                <\/span>\n              <\/p>\n<\/td>\n<td colspan=\"3\" class=\"prngen6\">\n<p class=\"prnews_p\">\n                <span class=\"prnews_span\">6,335<\/span>\n              <\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"prngen4\">\n<p class=\"prnews_p\">\n                <span class=\"prnews_span\">Depreciation and amortization<\/span>\n              <\/p>\n<\/td>\n<td colspan=\"3\" class=\"prngen11\">\n<p class=\"prnews_p\">\n                <span class=\"prnews_span\"><br \/>\n                  <b>415<\/b><br \/>\n                <\/span>\n              <\/p>\n<\/td>\n<td colspan=\"4\" class=\"prngen11\">\n<p class=\"prnews_p\">\n                <span class=\"prnews_span\">411<\/span>\n              <\/p>\n<\/td>\n<td class=\"prngen6\">\n              \n            <\/td>\n<td colspan=\"3\" class=\"prngen11\">\n<p class=\"prnews_p\">\n                <span class=\"prnews_span\"><br \/>\n                  <b>1,243<\/b><br \/>\n                <\/span>\n              <\/p>\n<\/td>\n<td colspan=\"3\" class=\"prngen11\">\n<p class=\"prnews_p\">\n                <span class=\"prnews_span\">1,177<\/span>\n              <\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"prngen4\">\n<p class=\"prnews_p\">\n                <span class=\"prnews_span\"><br \/>\n                  <b>Total operating expenses (excl. COGS)<\/b><br \/>\n                <\/span>\n              <\/p>\n<\/td>\n<td colspan=\"3\" class=\"prngen11\">\n<p class=\"prnews_p\">\n                <span class=\"prnews_span\"><br \/>\n                  <b>2,259<\/b><br \/>\n                <\/span>\n              <\/p>\n<\/td>\n<td colspan=\"4\" class=\"prngen11\">\n<p class=\"prnews_p\">\n                <span class=\"prnews_span\">2,965<\/span>\n              <\/p>\n<\/td>\n<td class=\"prngen11\">\n              \n            <\/td>\n<td colspan=\"3\" class=\"prngen11\">\n<p class=\"prnews_p\">\n                <span class=\"prnews_span\"><br \/>\n                  <b>7,402<\/b><br \/>\n                <\/span>\n              <\/p>\n<\/td>\n<td colspan=\"3\" class=\"prngen11\">\n<p class=\"prnews_p\">\n                <span class=\"prnews_span\">8,850<\/span>\n              <\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"prngen6\">\n              \n            <\/td>\n<td colspan=\"3\" class=\"prngen6\">\n              \n            <\/td>\n<td colspan=\"4\" class=\"prngen6\">\n              \n            <\/td>\n<td class=\"prngen6\">\n              \n            <\/td>\n<td colspan=\"3\" class=\"prngen6\">\n              \n            <\/td>\n<td colspan=\"3\" class=\"prngen6\">\n              \n            <\/td>\n<\/tr>\n<tr>\n<td class=\"prngen4\">\n<p class=\"prnews_p\">\n                <span class=\"prnews_span\"><br \/>\n                  <b>Operating profit<\/b><br \/>\n                <\/span>\n              <\/p>\n<\/td>\n<td colspan=\"3\" class=\"prngen11\">\n<p class=\"prnews_p\">\n                <span class=\"prnews_span\"><br \/>\n                  <b>3,870<\/b><br \/>\n                <\/span>\n              <\/p>\n<\/td>\n<td colspan=\"4\" class=\"prngen11\">\n<p class=\"prnews_p\">\n                <span class=\"prnews_span\">478<\/span>\n              <\/p>\n<\/td>\n<td class=\"prngen6\">\n              \n            <\/td>\n<td colspan=\"3\" class=\"prngen11\">\n<p class=\"prnews_p\">\n                <span class=\"prnews_span\"><br \/>\n                  <b>2,283<\/b><br \/>\n                <\/span>\n              <\/p>\n<\/td>\n<td colspan=\"3\" class=\"prngen11\">\n<p class=\"prnews_p\">\n                <span class=\"prnews_span\">5,554<\/span>\n              <\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"prngen12\">\n<p class=\"prnews_p\">\n                <span class=\"prnews_span\">Total other expenses (income)<\/span>\n              <\/p>\n<\/td>\n<td colspan=\"3\" class=\"prnsbts prnsbr1 prnvab prnsbbs prntar prnpl6 prnsbl1\">\n<p class=\"prnews_p\">\n                <span class=\"prnews_span\"><br \/>\n                  <b>(737)<\/b><br \/>\n                <\/span>\n              <\/p>\n<\/td>\n<td colspan=\"4\" class=\"prngen8\">\n<p class=\"prnews_p\">\n                <span class=\"prnews_span\">146<\/span>\n              <\/p>\n<\/td>\n<td class=\"prngen6\">\n              \n            <\/td>\n<td colspan=\"3\" class=\"prngen8\">\n<p class=\"prnews_p\">\n                <span class=\"prnews_span\"><br \/>\n                  <b>1,075<\/b><br \/>\n                <\/span>\n              <\/p>\n<\/td>\n<td colspan=\"3\" class=\"prngen8\">\n<p class=\"prnews_p\">\n                <span class=\"prnews_span\">1,657<\/span>\n              <\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"prngen7\">\n<p class=\"prnews_p\">\n                <span class=\"prnews_span\"><br \/>\n                  <b>Income before income taxes<\/b><br \/>\n                <\/span>\n              <\/p>\n<\/td>\n<td colspan=\"3\" class=\"prngen6\">\n<p class=\"prnews_p\">\n                <span class=\"prnews_span\"><br \/>\n                  <b>4,607<\/b><br \/>\n                <\/span>\n              <\/p>\n<\/td>\n<td colspan=\"4\" class=\"prngen6\">\n<p class=\"prnews_p\">\n                <span class=\"prnews_span\">332<\/span>\n              <\/p>\n<\/td>\n<td class=\"prngen6\">\n              \n            <\/td>\n<td colspan=\"3\" class=\"prngen6\">\n<p class=\"prnews_p\">\n                <span class=\"prnews_span\"><br \/>\n                  <b>1,208<\/b><br \/>\n                <\/span>\n              <\/p>\n<\/td>\n<td colspan=\"3\" class=\"prngen6\">\n<p class=\"prnews_p\">\n                <span class=\"prnews_span\">3,897<\/span>\n              <\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"prngen4\">\n<p class=\"prnews_p\">\n                <span class=\"prnews_span\">Deferred income tax expense<\/span>\n              <\/p>\n<\/td>\n<td colspan=\"3\" class=\"prngen11\">\n<p class=\"prnews_p\">\n                <span class=\"prnews_span\"><br \/>\n                  <b>399<\/b><br \/>\n                <\/span>\n              <\/p>\n<\/td>\n<td colspan=\"4\" class=\"prngen11\">\n<p class=\"prnews_p\">\n                <span class=\"prnews_span\">244<\/span>\n              <\/p>\n<\/td>\n<td class=\"prngen6\">\n              \n            <\/td>\n<td colspan=\"3\" class=\"prngen11\">\n<p class=\"prnews_p\">\n                <span class=\"prnews_span\"><br \/>\n                  <b>579<\/b><br \/>\n                <\/span>\n              <\/p>\n<\/td>\n<td colspan=\"3\" class=\"prngen11\">\n<p class=\"prnews_p\">\n                <span class=\"prnews_span\">1,559<\/span>\n              <\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"prnsbtbl prnsbr1 prnvab prnsbbs prnpl6 prnsbl1 prnpr6\">\n<p class=\"prnews_p\">\n                <span class=\"prnews_span\"><br \/>\n                  <b>Net income<\/b><br \/>\n                <\/span>\n              <\/p>\n<\/td>\n<td colspan=\"3\" class=\"prngen15\">\n<p class=\"prnews_p\">\n                <span class=\"prnews_span\"><br \/>\n                  <b>4,208<\/b><br \/>\n                <\/span>\n              <\/p>\n<\/td>\n<td colspan=\"4\" class=\"prngen15\">\n<p class=\"prnews_p\">\n                <span class=\"prnews_span\">88<\/span>\n              <\/p>\n<\/td>\n<td class=\"prngen6\">\n              \n            <\/td>\n<td colspan=\"3\" class=\"prngen15\">\n<p class=\"prnews_p\">\n                <span class=\"prnews_span\"><br \/>\n                  <b>629<\/b><br \/>\n                <\/span>\n              <\/p>\n<\/td>\n<td colspan=\"3\" class=\"prngen15\">\n<p class=\"prnews_p\">\n                <span class=\"prnews_span\">2,338<\/span>\n              <\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"prnsbtbl prnsbr1 prnvab prnsbb1 prnpl6 prnsbl1 prnpr6\">\n<p class=\"prnews_p\">\n                <span class=\"prnews_span\"><br \/>\n                  <b>Net income per share<\/b><br \/>\n                <\/span>\n              <\/p>\n<\/td>\n<td colspan=\"3\" class=\"prngen17\">\n              \n            <\/td>\n<td colspan=\"4\" class=\"prngen17\">\n              \n            <\/td>\n<td class=\"prngen6\">\n              \n            <\/td>\n<td colspan=\"3\" class=\"prngen17\">\n              \n            <\/td>\n<td colspan=\"3\" class=\"prngen17\">\n              \n            <\/td>\n<\/tr>\n<tr>\n<td class=\"prngen18\">\n<p class=\"prnews_p\">\n                <span class=\"prnews_span\">&#8211; Basic<\/span>\n              <\/p>\n<\/td>\n<td colspan=\"2\" class=\"prngen6\">\n<p class=\"prnews_p\">\n                <span class=\"prnews_span\"><br \/>\n                  <b>$<\/b><br \/>\n                <\/span>\n              <\/p>\n<\/td>\n<td class=\"prngen6\">\n<p class=\"prnews_p\">\n                <span class=\"prnews_span\"><br \/>\n                  <b>0.20<\/b><br \/>\n                <\/span>\n              <\/p>\n<\/td>\n<td colspan=\"3\" class=\"prngen6\">\n<p class=\"prnews_p\">\n                <span class=\"prnews_span\">$<\/span>\n              <\/p>\n<\/td>\n<td class=\"prngen6\">\n<p class=\"prnews_p\">\n                <span class=\"prnews_span\">&#8211;<\/span>\n              <\/p>\n<\/td>\n<td class=\"prngen6\">\n              \n            <\/td>\n<td colspan=\"2\" class=\"prngen6\">\n<p class=\"prnews_p\">\n                <span class=\"prnews_span\"><br \/>\n                  <b>$<\/b><br \/>\n                <\/span>\n              <\/p>\n<\/td>\n<td class=\"prngen6\">\n<p class=\"prnews_p\">\n                <span class=\"prnews_span\"><br \/>\n                  <b>0.03<\/b><br \/>\n                <\/span>\n              <\/p>\n<\/td>\n<td colspan=\"2\" class=\"prngen6\">\n<p class=\"prnews_p\">\n                <span class=\"prnews_span\">$<\/span>\n              <\/p>\n<\/td>\n<td class=\"prngen6\">\n<p class=\"prnews_p\">\n                <span class=\"prnews_span\">0.11<\/span>\n              <\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"prngen19\">\n<p class=\"prnews_p\">\n                <span class=\"prnews_span\">&#8211; Diluted<\/span>\n              <\/p>\n<\/td>\n<td colspan=\"2\" class=\"prngen11\">\n<p class=\"prnews_p\">\n                <span class=\"prnews_span\"><br \/>\n                  <b>$<\/b><br \/>\n                <\/span>\n              <\/p>\n<\/td>\n<td class=\"prngen11\">\n<p class=\"prnews_p\">\n                <span class=\"prnews_span\"><br \/>\n                  <b>0.19<\/b><br \/>\n                <\/span>\n              <\/p>\n<\/td>\n<td colspan=\"3\" class=\"prngen11\">\n<p class=\"prnews_p\">\n                <span class=\"prnews_span\">$<\/span>\n              <\/p>\n<\/td>\n<td class=\"prngen11\">\n<p class=\"prnews_p\">\n                <span class=\"prnews_span\">&#8211;<\/span>\n              <\/p>\n<\/td>\n<td class=\"prngen6\">\n              \n            <\/td>\n<td colspan=\"2\" class=\"prngen11\">\n<p class=\"prnews_p\">\n                <span class=\"prnews_span\"><br \/>\n                  <b>$<\/b><br \/>\n                <\/span>\n              <\/p>\n<\/td>\n<td class=\"prngen11\">\n<p class=\"prnews_p\">\n                <span class=\"prnews_span\"><br \/>\n                  <b>0.03<\/b><br \/>\n                <\/span>\n              <\/p>\n<\/td>\n<td colspan=\"2\" class=\"prngen11\">\n<p class=\"prnews_p\">\n                <span class=\"prnews_span\">$<\/span>\n              <\/p>\n<\/td>\n<td class=\"prngen11\">\n<p class=\"prnews_p\">\n                <span class=\"prnews_span\">0.11<\/span>\n              <\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"prngen7\">\n<p class=\"prnews_p\">\n                <span class=\"prnews_span\">Weighted average number of common shares<\/span>\n              <\/p>\n<\/td>\n<td colspan=\"3\" class=\"prngen6\">\n              \n            <\/td>\n<td colspan=\"4\" class=\"prngen6\">\n              \n            <\/td>\n<td class=\"prngen6\">\n              \n            <\/td>\n<td colspan=\"3\" class=\"prngen17\">\n              \n            <\/td>\n<td colspan=\"3\" class=\"prngen17\">\n              \n            <\/td>\n<\/tr>\n<tr>\n<td class=\"prngen18\">\n<p class=\"prnews_p\">\n                <span class=\"prnews_span\">&#8211; Basic<\/span>\n              <\/p>\n<\/td>\n<td colspan=\"3\" class=\"prngen6\">\n<p class=\"prnews_p\">\n                <span class=\"prnews_span\"><br \/>\n                  <b>20,648,448<\/b><br \/>\n                <\/span>\n              <\/p>\n<\/td>\n<td colspan=\"4\" class=\"prngen6\">\n<p class=\"prnews_p\">\n                <span class=\"prnews_span\">20,921,387<\/span>\n              <\/p>\n<\/td>\n<td class=\"prngen6\">\n              \n            <\/td>\n<td colspan=\"3\" class=\"prngen6\">\n<p class=\"prnews_p\">\n                <span class=\"prnews_span\"><br \/>\n                  <b>20,665,803<\/b><br \/>\n                <\/span>\n              <\/p>\n<\/td>\n<td colspan=\"3\" class=\"prngen6\">\n<p class=\"prnews_p\">\n                <span class=\"prnews_span\">20,984,502<\/span>\n              <\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"prngen19\">\n<p class=\"prnews_p\">\n                <span class=\"prnews_span\">&#8211; Diluted<\/span>\n              <\/p>\n<\/td>\n<td colspan=\"3\" class=\"prngen11\">\n<p class=\"prnews_p\">\n                <span class=\"prnews_span\"><br \/>\n                  <b>21,796,236<\/b><br \/>\n                <\/span>\n              <\/p>\n<\/td>\n<td colspan=\"4\" class=\"prngen11\">\n<p class=\"prnews_p\">\n                <span class=\"prnews_span\">22,705,677<\/span>\n              <\/p>\n<\/td>\n<td class=\"prngen11\">\n              \n            <\/td>\n<td colspan=\"3\" class=\"prngen11\">\n<p class=\"prnews_p\">\n                <span class=\"prnews_span\"><br \/>\n                  <b>21,995,583<\/b><br \/>\n                <\/span>\n              <\/p>\n<\/td>\n<td colspan=\"3\" class=\"prngen11\">\n<p class=\"prnews_p\">\n                <span class=\"prnews_span\">22,442,250<\/span>\n              <\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"prngen7\">\n<p class=\"prnews_p\">\n                <span class=\"prnews_span\"><br \/>\n                  <b>Selected Balance Sheet Information<\/b><br \/>\n                <\/span>\n              <\/p>\n<\/td>\n<td colspan=\"3\" class=\"prngen6\">\n              \n            <\/td>\n<td colspan=\"4\" class=\"prngen6\">\n              \n            <\/td>\n<td class=\"prngen6\">\n              \n            <\/td>\n<td colspan=\"3\" class=\"prngen6\">\n              \n            <\/td>\n<td colspan=\"3\" class=\"prngen6\">\n              \n            <\/td>\n<\/tr>\n<tr>\n<td class=\"prngen7\">\n<p class=\"prnews_p\">\n                <span class=\"prnews_span\">Cash and cash equivalents, end of period<\/span>\n              <\/p>\n<\/td>\n<td colspan=\"3\" class=\"prngen6\">\n<p class=\"prnews_p\">\n                <span class=\"prnews_span\"><br \/>\n                  <b>13,856<\/b><br \/>\n                <\/span>\n              <\/p>\n<\/td>\n<td colspan=\"4\" class=\"prngen6\">\n<p class=\"prnews_p\">\n                <span class=\"prnews_span\">13,005<\/span>\n              <\/p>\n<\/td>\n<td class=\"prngen6\">\n              \n            <\/td>\n<td colspan=\"3\" class=\"prngen6\">\n<p class=\"prnews_p\">\n                <span class=\"prnews_span\"><br \/>\n                  <b>13,856<\/b><br \/>\n                <\/span>\n              <\/p>\n<\/td>\n<td colspan=\"3\" class=\"prngen6\">\n<p class=\"prnews_p\">\n                <span class=\"prnews_span\">13,005<\/span>\n              <\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"prngen7\">\n<p class=\"prnews_p\">\n                <span class=\"prnews_span\">Long-term debt<\/span>\n              <\/p>\n<\/td>\n<td colspan=\"3\" class=\"prngen6\">\n<p class=\"prnews_p\">\n                <span class=\"prnews_span\"><br \/>\n                  <b>&#8211;<\/b><br \/>\n                <\/span>\n              <\/p>\n<\/td>\n<td colspan=\"4\" class=\"prngen6\">\n<p class=\"prnews_p\">\n                <span class=\"prnews_span\">3,564<\/span>\n              <\/p>\n<\/td>\n<td class=\"prngen6\">\n              \n            <\/td>\n<td colspan=\"3\" class=\"prngen6\">\n<p class=\"prnews_p\">\n                <span class=\"prnews_span\"><br \/>\n                  <b>&#8211;<\/b><br \/>\n                <\/span>\n              <\/p>\n<\/td>\n<td colspan=\"3\" class=\"prngen6\">\n<p class=\"prnews_p\">\n                <span class=\"prnews_span\">3,564<\/span>\n              <\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"prngen7\">\n<p class=\"prnews_p\">\n                <span class=\"prnews_span\"><br \/>\n                  <b>Selected Cash Flow Information<\/b><br \/>\n                <\/span>\n              <\/p>\n<\/td>\n<td colspan=\"3\" class=\"prngen6\">\n              \n            <\/td>\n<td colspan=\"4\" class=\"prngen6\">\n              \n            <\/td>\n<td class=\"prngen6\">\n              \n            <\/td>\n<td colspan=\"3\" class=\"prngen6\">\n              \n            <\/td>\n<td colspan=\"3\" class=\"prngen6\">\n              \n            <\/td>\n<\/tr>\n<tr>\n<td class=\"prngen7\">\n<p class=\"prnews_p\">\n                <span class=\"prnews_span\">Cash provided by operating activities<\/span>\n              <\/p>\n<\/td>\n<td colspan=\"3\" class=\"prngen6\">\n<p class=\"prnews_p\">\n                <span class=\"prnews_span\"><br \/>\n                  <b>4,693<\/b><br \/>\n                <\/span>\n              <\/p>\n<\/td>\n<td colspan=\"4\" class=\"prngen6\">\n<p class=\"prnews_p\">\n                <span class=\"prnews_span\">1,632<\/span>\n              <\/p>\n<\/td>\n<td class=\"prngen6\">\n              \n            <\/td>\n<td colspan=\"3\" class=\"prngen6\">\n<p class=\"prnews_p\">\n                <span class=\"prnews_span\"><br \/>\n                  <b>5,043<\/b><br \/>\n                <\/span>\n              <\/p>\n<\/td>\n<td colspan=\"3\" class=\"prngen6\">\n<p class=\"prnews_p\">\n                <span class=\"prnews_span\">5,254<\/span>\n              <\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"prngen7\">\n<p class=\"prnews_p\">\n                <span class=\"prnews_span\">Cash used in investing activities<\/span>\n              <\/p>\n<\/td>\n<td colspan=\"3\" class=\"prngen20\">\n<p class=\"prnews_p\">\n                <span class=\"prnews_span\"><br \/>\n                  <b>(1)<\/b><br \/>\n                <\/span>\n              <\/p>\n<\/td>\n<td colspan=\"4\" class=\"prngen20\">\n<p class=\"prnews_p\">\n                <span class=\"prnews_span\">(55)<\/span>\n              <\/p>\n<\/td>\n<td class=\"prngen6\">\n              \n            <\/td>\n<td colspan=\"3\" class=\"prngen20\">\n<p class=\"prnews_p\">\n                <span class=\"prnews_span\"><br \/>\n                  <b>(62)<\/b><br \/>\n                <\/span>\n              <\/p>\n<\/td>\n<td colspan=\"3\" class=\"prngen20\">\n<p class=\"prnews_p\">\n                <span class=\"prnews_span\">(169)<\/span>\n              <\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"prngen4\">\n<p class=\"prnews_p\">\n                <span class=\"prnews_span\">Cash used in financing activities<\/span>\n              <\/p>\n<\/td>\n<td colspan=\"3\" class=\"prngen21\">\n<p class=\"prnews_p\">\n                <span class=\"prnews_span\"><br \/>\n                  <b>(90)<\/b><br \/>\n                <\/span>\n              <\/p>\n<\/td>\n<td colspan=\"4\" class=\"prngen21\">\n<p class=\"prnews_p\">\n                <span class=\"prnews_span\">(263)<\/span>\n              <\/p>\n<\/td>\n<td class=\"prngen11\">\n              \n            <\/td>\n<td colspan=\"3\" class=\"prngen21\">\n<p class=\"prnews_p\">\n                <span class=\"prnews_span\"><br \/>\n                  <b>(382)<\/b><br \/>\n                <\/span>\n              <\/p>\n<\/td>\n<td colspan=\"3\" class=\"prngen21\">\n<p class=\"prnews_p\">\n                <span class=\"prnews_span\">(666)<\/span>\n              <\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"prngen6\">\n              \n            <\/td>\n<td colspan=\"3\" class=\"prngen6\">\n              \n            <\/td>\n<td colspan=\"4\" class=\"prngen6\">\n              \n            <\/td>\n<td class=\"prngen6\">\n              \n            <\/td>\n<td colspan=\"3\" class=\"prngen6\">\n              \n            <\/td>\n<td colspan=\"3\" class=\"prngen6\">\n              \n            <\/td>\n<\/tr>\n<\/table><\/div>\n<p \/>\n<p \/>\n<p>\n        <b>Revenue<br \/><\/b>The Company generates revenue from its three reportable segments: 1) Commercial Skincare (&#8220;Commercial&#8221;), which manufactures branded non-prescription skincare products for sale in both the Canadian and international markets; 2) Licensing and Royalties (&#8220;Licensing&#8221;), which includes revenue from the licensing of intellectual property related to Pliaglis or for the use of its transdermal delivery technologies; and 3) Manufacturing and Services (&#8220;Manufacturing&#8221;), which includes revenue from contract manufacturing and product development services (&#8220;CDMO&#8221;) offered to our clients. <\/p>\n<p>For the three months ended <span class=\"xn-chron\">September 30, 2020<\/span>, total revenue was <span class=\"xn-money\">$7,301<\/span> compared to <span class=\"xn-money\">$4,906<\/span> for the three months ended <span class=\"xn-chron\">September 30, 2019<\/span>, representing a year-over-year increase of <span class=\"xn-money\">$2,395<\/span>. The increase came primarily from the Licensing segment, representing <span class=\"xn-money\">$2,462<\/span>, as a result of the Taro Amendment concluded during the quarter of <span class=\"xn-money\">$4,483<\/span>, and to a lesser extent from the Commercial Skincare segment, representing a slight increase of <span class=\"xn-money\">$77<\/span>, primarily because of incremental sales of hand sanitizers and personal protective equipment starter kits. These increases were partly offset by the fourth and final cumulative sales milestone of <span class=\"xn-money\">$1,324<\/span><span class=\"xn-money\">(US$1,000)<\/span> in Q3-F2019 under the licensing agreement with Taro, which did not repeat in 2020, as well as lower royalties on global Pliaglis sales of <span class=\"xn-money\">$697<\/span> year-over-year, and a decrease of <span class=\"xn-money\">$144<\/span> in the Manufacturing segment, mainly due to a reduction in work volumes from our contract manufacturing clients due to pandemic-driven decreases in demand.<\/p>\n<p>For the nine months ended <span class=\"xn-chron\">September 30, 2020<\/span>, total revenue was <span class=\"xn-money\">$12,849<\/span> compared to <span class=\"xn-money\">$18,517<\/span> in the comparable nine-month period of 2019, representing a decrease of <span class=\"xn-money\">$5,668<\/span>. The Commercial Skincare and Manufacturing segments were impacted by <span class=\"xn-money\">$765<\/span> and <span class=\"xn-money\">$731<\/span>, respectively, as a result of lower demand for our products and services due to COVID-19-related shutdowns of personal services businesses such as spas and medispas throughout most of the second quarter of 2020. The Licensing segment posted a decrease of <span class=\"xn-money\">$4,172<\/span> year-over-year primarily due to the aggregate amount of <span class=\"xn-money\">$5,459<\/span> recognized in the first nine months of 2019 in connection with the Cantabria Agreement, which did not repeat in 2020, lower royalties on global Pliaglis sales\u00a0of <span class=\"xn-money\">$967<\/span>, and sales milestones of <span class=\"xn-money\">$2,645<\/span><span class=\"xn-money\">(US$2,000)<\/span>, which did not repeat in 2020, partly offset by the <span class=\"xn-money\">$4,483<\/span> received from the Taro Amendment.<\/p>\n<p>\n        <b>Gross Profit <br \/><\/b>For the three months ended <span class=\"xn-chron\">September 30, 2020<\/span>, total gross profit was <span class=\"xn-money\">$6,129<\/span>, representing a gross margin of 83.9%, compared to <span class=\"xn-money\">$3,443<\/span> or a gross margin of 70.2%\u00a0for the three months ended <span class=\"xn-chron\">September 30, 2019<\/span>. The year-over-year increase in gross profit of <span class=\"xn-money\">$2,686<\/span> and improvement in gross margin of 13.7% were primarily due to the increase in high margin Licensing revenue, as explained above, combined with lower costs associated to earning royalties on Pliaglis year-over-year.\u00a0 <\/p>\n<p>For the nine months ended <span class=\"xn-chron\">September 30, 2020<\/span>, total gross profit was <span class=\"xn-money\">$9,685<\/span>, representing a gross margin of 75.4%, compared to <span class=\"xn-money\">$14,404<\/span> or a gross margin of 77.8% for the comparative nine months of 2019. The decreases in gross profit of <span class=\"xn-money\">$4,719<\/span> and in gross margin of 2.4% were mainly due to: the decrease in high margin licensing revenue, the COVID-19 related business and product demand disruptions, as well as the timing and mix of CDMO sales driving the decreases in our Commercial Skincare and\u00a0 Manufacturing segments, respectively, partly offset by the lower costs associated to earning royalties on Pliaglis year-over-year.\u00a0 <\/p>\n<p>\n        <b>Operating Expenses (excluding COGS)<br \/><\/b>For the three and nine months ended <span class=\"xn-chron\">September 30, 2020<\/span>, total operating expenses were <span class=\"xn-money\">$2,259<\/span> and <span class=\"xn-money\">$7,402<\/span>, compared to <span class=\"xn-money\">$2,965<\/span> and <span class=\"xn-money\">$8,850<\/span>, for the three and nine months ended <span class=\"xn-chron\">September 30, 2019<\/span>. The year-over-year decreases <span class=\"xn-money\">$706<\/span> and <span class=\"xn-money\">$1,448<\/span> were mainly driven by lower selling, general and administrative (&#8220;SG&amp;A&#8221;) and R&amp;D expenses. Late in Q1-F2020, we initiated cash conservation measures in response to the COVID-19 pandemic which contributed to the year-over-year decreases. The measures included temporary layoffs and salary reductions. In addition, we had the benefit of wage subsidies under the CEWS program of <span class=\"xn-money\">$259<\/span> and <span class=\"xn-money\">$557<\/span>, respectively, for the three and nine months ended <span class=\"xn-chron\">September 30, 2020<\/span>, which were recorded against SG&amp;A-related compensation, as well as savings due to certain unfilled positions.<\/p>\n<p>\n        <b>Impairment of Intangible Assets<br \/><\/b>For the nine months ended <span class=\"xn-chron\">September 30, 2020<\/span>, the Company recognized an impairment charge of <span class=\"xn-money\">$1,918<\/span>, mainly to reflect the projected impact of the pandemic-driven decrease in demand for its non-prescription skincare products and contract manufacturing services on its long-term forecasts. <\/p>\n<p>\n        <b>Other Income &#8211; Taro Amendment<br \/><\/b>As part of the Taro Amendment concluded during the quarter, the Company recognized <span class=\"xn-money\">$668<\/span><span class=\"xn-money\">(US$500)<\/span> in connection with the termination of a non-financial clause regarding the supply of Pliaglis to non-U.S. territories.<\/p>\n<p>\n        <b>Income before Income Taxes<br \/><\/b>For the three months ended <span class=\"xn-chron\">September 30, 2020<\/span>, the Company reported income before income taxes of <span class=\"xn-money\">$4,607<\/span>, compared to <span class=\"xn-money\">$332<\/span> for the three months ended <span class=\"xn-chron\">September 30, 2019<\/span>. The year-over-year increase of <span class=\"xn-money\">$4,275<\/span> was mainly attributable to: 1) the incremental total gross margin of <span class=\"xn-money\">$2,686<\/span> across our segments, largely due to the amounts received under the Taro Amendment; 2) a reduction in R&amp;D and SG&amp;A expenses of <span class=\"xn-money\">$250<\/span> and <span class=\"xn-money\">$460<\/span>, respectively; 3) Other Income of <span class=\"xn-money\">$668<\/span> recognized as part of the Taro Amendment in connection with the termination of certain non-financial clauses; 4) a reduction in net interest expense of <span class=\"xn-money\">$74<\/span>; and 5) the favourable impact of foreign exchange variances in the amount of <span class=\"xn-money\">$141<\/span> year-over-year.<\/p>\n<p>For the nine months ended <span class=\"xn-chron\">September 30, 2020<\/span>, the Company reported income before income taxes of <span class=\"xn-money\">$1,208<\/span>, compared to <span class=\"xn-money\">$3,897<\/span> reported for the nine months ended <span class=\"xn-chron\">September 30, 2019<\/span>. The year-over-year decrease of <span class=\"xn-money\">$2,689<\/span> was mainly attributable to: 1) the reduction in gross margin of <span class=\"xn-money\">$4,156<\/span> across all segments, excluding the impacts of both the Cantabria Agreement as well as the Taro Amendment; 2) the benefit of the upfront payment and guaranteed minimum royalties under the Cantabria Agreement of <span class=\"xn-money\">$3,772<\/span>, net of contract termination fees recognized in Q2-F2019 which did not repeat; 3) the impairment charge of <span class=\"xn-money\">$1,918<\/span> taken in Q2-F2020; partly offset by 1) the aggregate impact of the Taro Amendment of <span class=\"xn-money\">$5,151<\/span>; 2) the decrease in SG&amp;A and R&amp;D expenses of <span class=\"xn-money\">$952<\/span> and <span class=\"xn-money\">$562<\/span>, respectively; 3) the reduction in net interest expense of <span class=\"xn-money\">$288<\/span>; and 4) the favourable impact of net foreign exchange variances in the amount of <span class=\"xn-money\">$270<\/span>.<\/p>\n<p>\n        <b>Cash and Cash Equivalents <br \/><\/b>Cash and cash equivalents were <span class=\"xn-money\">$13<\/span>,856\u00a0at <span class=\"xn-chron\">September 30, 2020<\/span> compared to\u00a0$13,005\u00a0at <span class=\"xn-chron\">September 30, 2019<\/span> and <span class=\"xn-money\">$9,265<\/span> at <span class=\"xn-chron\">June 30, 2020<\/span>, representing increases of $851\u00a0and <span class=\"xn-money\">$4,591<\/span>, respectively, mainly due to the cash received from the Taro Amendment. During the fourth quarter ended <span class=\"xn-chron\">December 31, 2019<\/span>, the Company repaid the outstanding balance of the Knight Loan in the amount of <span class=\"xn-money\">$3,570<\/span>.<\/p>\n<p>\n        <b><br \/>\n          <i>Non-IFRS Financial Measures<br \/><\/i><br \/>\n        <\/b>The Company reports its financial results in accordance with IFRS. However, we use certain non-IFRS financial measures to assess our Company&#8217;s performance. We believe these to be useful to management, investors, and other financial stakeholders in assessing Crescita&#8217;s performance from both a financial and operational standpoint. The non-IFRS measures used in this press release do not have any standardized meaning prescribed by IFRS and are therefore not comparable to similar measures presented by other issuers. These measures should be considered as supplemental in nature and not as a substitute for the related financial information prepared in accordance with IFRS. The following are the Company&#8217;s non-IFRS measures along with their respective definitions:<\/p>\n<ol type=\"1\">\n<li>EBITDA is defined as earnings before interest, income taxes, depreciation, and amortization. <\/li>\n<li>Adjusted EBITDA is defined as earnings before interest, income taxes, depreciation and amortization, other expenses or (income), share-based compensation costs, goodwill and intangible assets impairment, and foreign exchange (gains) or losses, as applicable. <\/li>\n<\/ol>\n<p \/>\n<p>Management believes that Adjusted EBITDA is an important measure of operating performance and cash flow and provides useful information to investors as it highlights trends in the underlying business that may not otherwise be apparent when relying solely on IFRS measures. A reconciliation of EBITDA and adjusted EBITDA to their closest IFRS measure can be found below.<\/p>\n<div>\n<table cellspacing=\"0\" cellpadding=\"0\" border=\"0\" class=\"prntblns\">\n<tr>\n<td rowspan=\"2\" class=\"prnsbt1 prnsbr1 prnvab prnsbbs prntal prnpl6 prnsbl1 prnpr6\">\n<p class=\"prnews_p\">\n                <span class=\"prnews_span\"><br \/>\n                  <i>In thousands of CAD dollars<\/i><br \/>\n                <\/span>\n              <\/p>\n<\/td>\n<td colspan=\"2\" class=\"prngen23\">\n<p class=\"prnews_p\">\n                <span class=\"prnews_span\"><br \/>\n                  <b>Three months ended <br \/>September 30,<\/b><br \/>\n                <\/span>\n              <\/p>\n<\/td>\n<td colspan=\"2\" class=\"prngen23\">\n<p class=\"prnews_p\">\n                <span class=\"prnews_span\"><br \/>\n                  <b>Nine months ended\u00a0 <br \/>September 30,<\/b><br \/>\n                <\/span>\n              <\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"prngen21 prnpr8\">\n<p class=\"prnews_p\">\n                <span class=\"prnews_span\"><br \/>\n                  <b>2020<\/b><br \/>\n                <\/span>\n              <\/p>\n<\/td>\n<td class=\"prngen24\">\n<p class=\"prnews_p\">\n                <span class=\"prnews_span\">2019<\/span>\n              <\/p>\n<\/td>\n<td class=\"prngen24\">\n<p class=\"prnews_p\">\n                <span class=\"prnews_span\"><br \/>\n                  <b>2020<\/b><br \/>\n                <\/span>\n              <\/p>\n<\/td>\n<td class=\"prngen24\">\n<p class=\"prnews_p\">\n                <span class=\"prnews_span\">2019<\/span>\n              <\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"prngen20 prnpr8\">\n              \n            <\/td>\n<td class=\"prngen25\">\n              \n            <\/td>\n<td class=\"prngen25\">\n              \n            <\/td>\n<td class=\"prngen25\">\n              \n            <\/td>\n<td class=\"prngen25\">\n              \n            <\/td>\n<\/tr>\n<tr>\n<td class=\"prngen26\">\n              \n            <\/td>\n<td class=\"prngen26\">\n              \n            <\/td>\n<td class=\"prngen26\">\n              \n            <\/td>\n<td class=\"prngen26\">\n              \n            <\/td>\n<td class=\"prngen26\">\n              \n            <\/td>\n<\/tr>\n<tr>\n<td class=\"prngen27\">\n<p class=\"prnews_p\">\n                <span class=\"prnews_span\">Net income<\/span>\n              <\/p>\n<\/td>\n<td class=\"prngen25\">\n<p class=\"prnews_p\">\n                <span class=\"prnews_span\"><br \/>\n                  <b>4,208<\/b><br \/>\n                <\/span>\n              <\/p>\n<\/td>\n<td class=\"prngen25\">\n<p class=\"prnews_p\">\n                <span class=\"prnews_span\">88<\/span>\n              <\/p>\n<\/td>\n<td class=\"prngen25\">\n<p class=\"prnews_p\">\n                <span class=\"prnews_span\"><br \/>\n                  <b>629<\/b><br \/>\n                <\/span>\n              <\/p>\n<\/td>\n<td class=\"prngen25\">\n<p class=\"prnews_p\">\n                <span class=\"prnews_span\">2,338<\/span>\n              <\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"prngen25\">\n              \n            <\/td>\n<td class=\"prngen25\">\n              \n            <\/td>\n<td class=\"prngen25\">\n              \n            <\/td>\n<td class=\"prngen25\">\n              \n            <\/td>\n<td class=\"prngen25\">\n              \n            <\/td>\n<\/tr>\n<tr>\n<td class=\"prngen7\">\n<p class=\"prnews_p\">\n                <span class=\"prnews_span\"><br \/>\n                  <b><br \/>\n                    <i>Add:<\/i><br \/>\n                  <\/b><br \/>\n                <\/span>\n              <\/p>\n<\/td>\n<td class=\"prngen25\">\n              \n            <\/td>\n<td class=\"prngen25\">\n              \n            <\/td>\n<td class=\"prngen25\">\n              \n            <\/td>\n<td class=\"prngen25\">\n              \n            <\/td>\n<\/tr>\n<tr>\n<td class=\"prngen25\">\n              \n            <\/td>\n<td class=\"prngen25\">\n              \n            <\/td>\n<td class=\"prngen25\">\n              \n            <\/td>\n<td class=\"prngen25\">\n              \n            <\/td>\n<td class=\"prngen25\">\n              \n            <\/td>\n<\/tr>\n<tr>\n<td class=\"prngen7\">\n<p class=\"prnews_p\">\n                <span class=\"prnews_span\">Depreciation and amortization<\/span>\n              <\/p>\n<\/td>\n<td class=\"prngen25\">\n<p class=\"prnews_p\">\n                <span class=\"prnews_span\"><br \/>\n                  <b>415<\/b><br \/>\n                <\/span>\n              <\/p>\n<\/td>\n<td class=\"prngen25\">\n<p class=\"prnews_p\">\n                <span class=\"prnews_span\">411<\/span>\n              <\/p>\n<\/td>\n<td class=\"prngen25\">\n<p class=\"prnews_p\">\n                <span class=\"prnews_span\"><br \/>\n                  <b>1,243<\/b><br \/>\n                <\/span>\n              <\/p>\n<\/td>\n<td class=\"prngen25\">\n<p class=\"prnews_p\">\n                <span class=\"prnews_span\">1,177<\/span>\n              <\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"prngen27\">\n<p class=\"prnews_p\">\n                <span class=\"prnews_span\">Interest, net<\/span>\n              <\/p>\n<\/td>\n<td class=\"prngen28\">\n<p class=\"prnews_p\">\n                <span class=\"prnews_span\"><br \/>\n                  <b>(5)<\/b><br \/>\n                <\/span>\n              <\/p>\n<\/td>\n<td class=\"prngen25\">\n<p class=\"prnews_p\">\n                <span class=\"prnews_span\">69<\/span>\n              <\/p>\n<\/td>\n<td class=\"prngen28\">\n<p class=\"prnews_p\">\n                <span class=\"prnews_span\"><br \/>\n                  <b>(10)<\/b><br \/>\n                <\/span>\n              <\/p>\n<\/td>\n<td class=\"prngen25\">\n<p class=\"prnews_p\">\n                <span class=\"prnews_span\">278<\/span>\n              <\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"prngen7\">\n<p class=\"prnews_p\">\n                <span class=\"prnews_span\">Deferred income tax expense<\/span>\n              <\/p>\n<\/td>\n<td class=\"prngen25\">\n<p class=\"prnews_p\">\n                <span class=\"prnews_span\"><br \/>\n                  <b>399<\/b><br \/>\n                <\/span>\n              <\/p>\n<\/td>\n<td class=\"prngen25\">\n<p class=\"prnews_p\">\n                <span class=\"prnews_span\">244<\/span>\n              <\/p>\n<\/td>\n<td class=\"prngen25\">\n<p class=\"prnews_p\">\n                <span class=\"prnews_span\"><br \/>\n                  <b>579<\/b><br \/>\n                <\/span>\n              <\/p>\n<\/td>\n<td class=\"prngen25\">\n<p class=\"prnews_p\">\n                <span class=\"prnews_span\">1,559<\/span>\n              <\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"prngen12\">\n<p class=\"prnews_p\">\n                <span class=\"prnews_span\"><br \/>\n                  <b>EBITDA<\/b><br \/>\n                <\/span>\n              <\/p>\n<\/td>\n<td class=\"prngen29\">\n<p class=\"prnews_p\">\n                <span class=\"prnews_span\"><br \/>\n                  <b>5,017<\/b><br \/>\n                <\/span>\n              <\/p>\n<\/td>\n<td class=\"prngen29\">\n<p class=\"prnews_p\">\n                <span class=\"prnews_span\">812<\/span>\n              <\/p>\n<\/td>\n<td class=\"prngen29\">\n<p class=\"prnews_p\">\n                <span class=\"prnews_span\"><br \/>\n                  <b>2,441<\/b><br \/>\n                <\/span>\n              <\/p>\n<\/td>\n<td class=\"prngen29\">\n<p class=\"prnews_p\">\n                <span class=\"prnews_span\">5,352<\/span>\n              <\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"prngen7\">\n<p class=\"prnews_p\">\n                <span class=\"prnews_span\"><br \/>\n                  <b><br \/>\n                    <i>Add:<\/i><br \/>\n                  <\/b><br \/>\n                <\/span>\n              <\/p>\n<\/td>\n<td class=\"prngen25\">\n              \n            <\/td>\n<td class=\"prngen25\">\n              \n            <\/td>\n<td class=\"prngen25\">\n              \n            <\/td>\n<td class=\"prngen25\">\n              \n            <\/td>\n<\/tr>\n<tr>\n<td class=\"prngen25\">\n              \n            <\/td>\n<td class=\"prngen25\">\n              \n            <\/td>\n<td class=\"prngen25\">\n              \n            <\/td>\n<td class=\"prngen25\">\n              \n            <\/td>\n<td class=\"prngen25\">\n              \n            <\/td>\n<\/tr>\n<tr>\n<td class=\"prngen7\">\n<p class=\"prnews_p\">\n                <span class=\"prnews_span\">Share-based compensation<\/span>\n              <\/p>\n<\/td>\n<td class=\"prngen25\">\n<p class=\"prnews_p\">\n                <span class=\"prnews_span\"><br \/>\n                  <b>31<\/b><br \/>\n                <\/span>\n              <\/p>\n<\/td>\n<td class=\"prngen25\">\n<p class=\"prnews_p\">\n                <span class=\"prnews_span\">50<\/span>\n              <\/p>\n<\/td>\n<td class=\"prngen25\">\n<p class=\"prnews_p\">\n                <span class=\"prnews_span\"><br \/>\n                  <b>121<\/b><br \/>\n                <\/span>\n              <\/p>\n<\/td>\n<td class=\"prngen25\">\n<p class=\"prnews_p\">\n                <span class=\"prnews_span\">247<\/span>\n              <\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"prngen27\">\n<p class=\"prnews_p\">\n                <span class=\"prnews_span\">Foreign exchange loss<\/span>\n              <\/p>\n<\/td>\n<td class=\"prngen25\">\n<p class=\"prnews_p\">\n                <span class=\"prnews_span\"><br \/>\n                  <b>&#8211;<\/b><br \/>\n                <\/span>\n              <\/p>\n<\/td>\n<td class=\"prngen25\">\n<p class=\"prnews_p\">\n                <span class=\"prnews_span\">77<\/span>\n              <\/p>\n<\/td>\n<td class=\"prngen25\">\n<p class=\"prnews_p\">\n                <span class=\"prnews_span\"><br \/>\n                  <b>&#8211;<\/b><br \/>\n                <\/span>\n              <\/p>\n<\/td>\n<td class=\"prngen25\">\n<p class=\"prnews_p\">\n                <span class=\"prnews_span\">105<\/span>\n              <\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"prngen27\">\n<p class=\"prnews_p\">\n                <span class=\"prnews_span\">Other expense &#8211; Termination costs<\/span>\n              <\/p>\n<\/td>\n<td class=\"prngen25\">\n<p class=\"prnews_p\">\n                <span class=\"prnews_span\"><br \/>\n                  <b>&#8211;<\/b><br \/>\n                <\/span>\n              <\/p>\n<\/td>\n<td class=\"prngen25\">\n<p class=\"prnews_p\">\n                <span class=\"prnews_span\">&#8211;<\/span>\n              <\/p>\n<\/td>\n<td class=\"prngen25\">\n<p class=\"prnews_p\">\n                <span class=\"prnews_span\"><br \/>\n                  <b>&#8211;<\/b><br \/>\n                <\/span>\n              <\/p>\n<\/td>\n<td class=\"prngen25\">\n<p class=\"prnews_p\">\n                <span class=\"prnews_span\">1,274<\/span>\n              <\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"prngen27\">\n<p class=\"prnews_p\">\n                <span class=\"prnews_span\">Intangible assets impairment<\/span>\n              <\/p>\n<\/td>\n<td class=\"prngen25\">\n<p class=\"prnews_p\">\n                <span class=\"prnews_span\"><br \/>\n                  <b>&#8211;<\/b><br \/>\n                <\/span>\n              <\/p>\n<\/td>\n<td class=\"prngen25\">\n<p class=\"prnews_p\">\n                <span class=\"prnews_span\">&#8211;<\/span>\n              <\/p>\n<\/td>\n<td class=\"prngen25\">\n<p class=\"prnews_p\">\n                <span class=\"prnews_span\"><br \/>\n                  <b>1,918<\/b><br \/>\n                <\/span>\n              <\/p>\n<\/td>\n<td class=\"prngen25\">\n<p class=\"prnews_p\">\n                <span class=\"prnews_span\">&#8211;<\/span>\n              <\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"prngen7\">\n<p class=\"prnews_p\">\n                <span class=\"prnews_span\"><br \/>\n                  <b><br \/>\n                    <i>Less:<\/i><br \/>\n                  <\/b><br \/>\n                <\/span>\n              <\/p>\n<\/td>\n<td class=\"prngen25\">\n              \n            <\/td>\n<td class=\"prngen25\">\n              \n            <\/td>\n<td class=\"prngen25\">\n              \n            <\/td>\n<td class=\"prngen25\">\n              \n            <\/td>\n<\/tr>\n<tr>\n<td class=\"prngen25\">\n              \n            <\/td>\n<td class=\"prngen25\">\n              \n            <\/td>\n<td class=\"prngen25\">\n              \n            <\/td>\n<td class=\"prngen25\">\n              \n            <\/td>\n<td class=\"prngen25\">\n              \n            <\/td>\n<\/tr>\n<tr>\n<td class=\"prngen7\">\n<p class=\"prnews_p\">\n                <span class=\"prnews_span\">Other income &#8211; Taro Amendment<\/span>\n              <\/p>\n<\/td>\n<td class=\"prngen25\">\n<p class=\"prnews_p\">\n                <span class=\"prnews_span\"><br \/>\n                  <b>668<\/b><br \/>\n                <\/span>\n              <\/p>\n<\/td>\n<td class=\"prngen25\">\n<p class=\"prnews_p\">\n                <span class=\"prnews_span\">&#8211;<\/span>\n              <\/p>\n<\/td>\n<td class=\"prngen25\">\n<p class=\"prnews_p\">\n                <span class=\"prnews_span\"><br \/>\n                  <b>668<\/b><br \/>\n                <\/span>\n              <\/p>\n<\/td>\n<td class=\"prngen25\">\n<p class=\"prnews_p\">\n                <span class=\"prnews_span\">&#8211;<\/span>\n              <\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"prngen7\">\n<p class=\"prnews_p\">\n                <span class=\"prnews_span\">Foreign exchange gain<\/span>\n              <\/p>\n<\/td>\n<td class=\"prngen25\">\n<p class=\"prnews_p\">\n                <span class=\"prnews_span\"><br \/>\n                  <b>64<\/b><br \/>\n                <\/span>\n              <\/p>\n<\/td>\n<td class=\"prngen25\">\n<p class=\"prnews_p\">\n                <span class=\"prnews_span\">&#8211;<\/span>\n              <\/p>\n<\/td>\n<td class=\"prngen25\">\n<p class=\"prnews_p\">\n                <span class=\"prnews_span\"><br \/>\n                  <b>165<\/b><br \/>\n                <\/span>\n              <\/p>\n<\/td>\n<td class=\"prngen25\">\n<p class=\"prnews_p\">\n                <span class=\"prnews_span\">&#8211;<\/span>\n              <\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"prngen12\">\n<p class=\"prnews_p\">\n                <span class=\"prnews_span\"><br \/>\n                  <b>Adjusted EBITDA<\/b><br \/>\n                <\/span>\n              <\/p>\n<\/td>\n<td class=\"prngen29\">\n<p class=\"prnews_p\">\n                <span class=\"prnews_span\"><br \/>\n                  <b>4,316<\/b><br \/>\n                <\/span>\n              <\/p>\n<\/td>\n<td class=\"prngen29\">\n<p class=\"prnews_p\">\n                <span class=\"prnews_span\">939<\/span>\n              <\/p>\n<\/td>\n<td class=\"prngen29\">\n<p class=\"prnews_p\">\n                <span class=\"prnews_span\"><br \/>\n                  <b>3,647<\/b><br \/>\n                <\/span>\n              <\/p>\n<\/td>\n<td class=\"prngen29\">\n<p class=\"prnews_p\">\n                <span class=\"prnews_span\">6,978<\/span>\n              <\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"prngen25\">\n              \n            <\/td>\n<td class=\"prngen25\">\n              \n            <\/td>\n<td class=\"prngen25\">\n              \n            <\/td>\n<td class=\"prngen25\">\n              \n            <\/td>\n<td class=\"prngen25\">\n              \n            <\/td>\n<\/tr>\n<tr>\n<td class=\"prngen25\">\n              \n            <\/td>\n<td class=\"prngen25\">\n              \n            <\/td>\n<td class=\"prngen25\">\n              \n            <\/td>\n<td class=\"prngen25\">\n              \n            <\/td>\n<td class=\"prngen25\">\n              \n            <\/td>\n<\/tr>\n<\/table><\/div>\n<p \/>\n<p>\u00a0<\/p>\n<p>\n        <b><br \/>\n          <i>Caution Concerning Limitations of Summary Financial Results Press Release<br \/><\/i><br \/>\n        <\/b>This summary earnings press release contains limited information meant to assist the reader in assessing Crescita&#8217;s performance, but it is not a suitable source of information for readers who are unfamiliar with Crescita and is not in any way a substitute for the Company&#8217;s Consolidated Audited Financial Statements and notes thereto, MD&amp;A and Annual Information Form (&#8220;AIF&#8221;).<\/p>\n<p>\n        <b>About<\/b><br \/>\n        <b>\u00a0<\/b><br \/>\n        <b>Crescita Therapeutics<\/b><br \/>\n        <b>\u00a0Inc.<br \/><\/b>Crescita (TSX: CTX and OTC US: CRRTF) is a growth-oriented, innovation-driven Canadian commercial dermatology company with in-house R&amp;D and manufacturing capabilities. The Company offers a portfolio of non-prescription skincare products and early to commercial stage prescription drug products and owns multiple proprietary drug delivery platforms that support the development of patented formulations that can facilitate the delivery of active ingredients into or through the skin. <\/p>\n<p>Supported by a sales force covering <span class=\"xn-location\">Canada<\/span> and executing a business to business to consumer marketing approach, Crescita sells its non-prescription skincare products domestically through spas, medispas, and medical aesthetic clinics, as well as internationally, through distributors. Crescita&#8217;s portfolio also includes a prescription product called Pliaglis<sup>\u00ae<\/sup>, that utilizes the Company&#8217;s proprietary phase-changing topical cream Peel technology, a part of the DuraPeel\u2122 family, which are self-occluding, film-forming cream\/gel formulations, that provide extended release delivery of the active ingredients to the site of application. Pliaglis is a topical local anesthetic cream that provides safe and effective local dermal analgesia on intact skin prior to superficial dermatological procedures. The product is currently approved in over 25 different countries and sold by commercial partners in the U.S., <span class=\"xn-location\">Italy<\/span>, <span class=\"xn-location\">Brazil<\/span>, sold in <span class=\"xn-location\">Canada<\/span> by the Company, and was most recently licensed to partners in Austria\u00a0and\u00a0Mexico and <span class=\"xn-location\">China<\/span>. <\/p>\n<p>Crescita&#8217;s expertise in product formulation and development can be leveraged in combination with its patented transdermal delivery technologies to develop and manufacture creams, liquids, gels, ointments and serums under its CDMO infrastructure. The Company operates out of a 50,000 square-foot facility located in <span class=\"xn-location\">Laval<\/span>, Qu\u00e9bec, which produces the majority of its non-prescription skincare products, such as LDR, Pro-Derm, Dermazulene and Alyria. Formulations manufactured by or for Crescita include cosmetics, natural health products and products with Drug Identification Numbers. For additional information, please visit <a target=\"_blank\" href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=2979578-1&amp;h=3771865463&amp;u=http%3A%2F%2Fwww.crescitatherapeutics.com%2F&amp;a=www.crescitatherapeutics.com\" rel=\"nofollow noopener noreferrer\">www.crescitatherapeutics.com<\/a>.<\/p>\n<p>\n        <b>Forward-Looking Statements <br \/><\/b>This press release contains &#8220;forward-looking information&#8221; as defined under Canadian securities laws (collectively, &#8220;forward-looking statements&#8221;). The words &#8220;plans&#8221;, &#8220;expects&#8221;, &#8220;does not expect&#8221;, &#8220;goals&#8221;, &#8220;seek&#8221;, &#8220;strategy&#8221;, &#8220;future&#8221;, &#8220;estimates&#8221;, &#8220;intends&#8221;, &#8220;anticipates&#8221;, &#8220;does not anticipate&#8221;, &#8220;projected&#8221;, &#8220;believes&#8221; or variations of such words and phrases or statements to the effect that certain actions, events or results &#8220;may&#8221;, &#8220;will&#8221;, &#8220;could&#8221;, &#8220;would&#8221;, &#8220;should&#8221;, &#8220;might&#8221;, &#8220;likely&#8221;, &#8220;occur&#8221;, &#8220;be achieved&#8221; &#8220;continue&#8221; or &#8220;temporary&#8221; \u00a0and similar expressions identify forward-looking statements and include statements regarding the Company&#8217;s plans, objectives and responses to the COVID-19 pandemic. In addition, any statements that refer to expectations, intentions, projections or other characterizations of future events or circumstances contain forward-looking statements.<\/p>\n<p>Forward-looking statements are not historical facts but instead represent management&#8217;s expectations, estimates, projections and assumptions regarding future events or circumstances. Such forward-looking statements are qualified in their entirety by the inherent risks, uncertainties and changes in circumstances surrounding future expectations which are difficult to predict and many of which are beyond the control of the Company. Forward-looking statements are necessarily based on a number of estimates and assumptions that, while considered reasonable by management of the Company as of the date of this press release, are inherently subject to significant business, economic and competitive uncertainties and contingencies. Material factors and assumptions used to develop the forward-looking statements, and material risk factors that could cause actual results to differ materially from the forward-looking statements, include but are not limited to the risks of, and future impacts related to, COVID-19, including the response of domestic and international governments to the virus; the impact of COVID-19 on the Company&#8217;s operations, personnel, supply chain, product sales, royalties, customer demand and financial flexibility; \u00a0changes in the business or affairs of Crescita; the ability of Crescita&#8217;s licensees to successfully market its products; competitive factors in the industries in which Crescita operates; relationships with customers, suppliers and licensees; changes in legal and regulatory requirements; foreign exchange and interest rates; prevailing economic conditions; and other factors, many of which are beyond the control of Crescita.\u00a0 <\/p>\n<p>Additional factors that could cause Crescita&#8217;s actual results and financial condition to differ materially from those indicated in the forward-looking statements include, among others, the risk factors included in Crescita&#8217;s most recent Annual Information Form under the heading &#8220;Risks Factors&#8221;, and as described from time to time in the reports and disclosure documents filed by Crescita with Canadian securities regulatory authorities and commissions. These and other factors should be considered carefully, and readers should not place undue reliance on Crescita&#8217;s forward-looking statements when making decisions, as forward-looking statements involve significant risks and uncertainties. Forward-looking statements should not be read as guarantees of future performance or results and will not necessarily be accurate indications of whether or not the times at or by which such performance or results will be achieved.<\/p>\n<p>All forward-looking statements are based only on information currently available to the Company and are made as of the date of this press release. Except as expressly required by applicable Canadian securities law, the Company assumes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise. All forward-looking statements in this press release are qualified by these cautionary statements.<\/p>\n<div class=\"PRN_ImbeddedAssetReference\" id=\"DivAssetPlaceHolder2\"><\/div>\n<p id=\"PURL\">\n        <img loading=\"lazy\" decoding=\"async\" title=\"Cision\" width=\"12\" height=\"12\" alt=\"Cision\" src=\"https:\/\/c212.net\/c\/img\/favicon.png?sn=MO89473&amp;sd=2020-11-12\" \/> View original content to download multimedia:<a id=\"PRNURL\" rel=\"nofollow\" href=\"http:\/\/www.prnewswire.com\/news-releases\/crescita-reports-third-quarter-2020-results-301171830.html\">http:\/\/www.prnewswire.com\/news-releases\/crescita-reports-third-quarter-2020-results-301171830.html<\/a><\/p>\n<p>SOURCE  Crescita Therapeutics Inc.<\/p>\n<\/p><\/div>\n<p>    <img decoding=\"async\" alt=\"\" src=\"https:\/\/rt.prnewswire.com\/rt.gif?NewsItemId=MO89473&amp;Transmission_Id=202011120730PR_NEWS_USPR_____MO89473&amp;DateId=20201112\" style=\"border:0px;width:1px;height:1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>PR Newswire Strong Ending Cash Balance of $13.9M LAVAL, QC, Nov. 12, 2020 \/CNW Telbec\/ Crescita Therapeutics Inc. (TSX: CTX) (OTC US: CRRTF) (&#8220;Crescita&#8221; or the &#8220;Company&#8221;), a growth-oriented, innovation-driven Canadian commercial dermatology company with in-house research &amp; development (&#8220;R&amp;D&#8221;) and manufacturing capabilities,\u00a0today reported its financial results for the third quarter ended September 30, 2020 (&#8220;Q3-F2020&#8221;). \u00a0All amounts presented are in thousands of Canadian dollars (&#8220;CAD&#8221;) unless otherwise noted. Financial Highlights \u00a0\u2013 Q3-F2020 vs. Q3-F2019 Revenue was $7,301 compared to $4,906, an increase of $2,395; In Q3-F2020, the Company amended its licensing agreement with commercial partner Taro Pharmaceuticals Inc. (&#8220;Taro&#8221;) for Pliaglis\u00ae in the U.S. and received a total of $5,151(US$3,855). Revenue was recorded as follows: $4,483 (US$3,355) as licensing &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/crescita-reports-third-quarter-2020-results\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Crescita Reports Third Quarter 2020 Results&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-379483","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Crescita Reports Third Quarter 2020 Results - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/crescita-reports-third-quarter-2020-results\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Crescita Reports Third Quarter 2020 Results - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"PR Newswire Strong Ending Cash Balance of $13.9M LAVAL, QC, Nov. 12, 2020 \/CNW Telbec\/ Crescita Therapeutics Inc. (TSX: CTX) (OTC US: CRRTF) (&#8220;Crescita&#8221; or the &#8220;Company&#8221;), a growth-oriented, innovation-driven Canadian commercial dermatology company with in-house research &amp; development (&#8220;R&amp;D&#8221;) and manufacturing capabilities,\u00a0today reported its financial results for the third quarter ended September 30, 2020 (&#8220;Q3-F2020&#8221;). \u00a0All amounts presented are in thousands of Canadian dollars (&#8220;CAD&#8221;) unless otherwise noted. Financial Highlights \u00a0\u2013 Q3-F2020 vs. Q3-F2019 Revenue was $7,301 compared to $4,906, an increase of $2,395; In Q3-F2020, the Company amended its licensing agreement with commercial partner Taro Pharmaceuticals Inc. (&#8220;Taro&#8221;) for Pliaglis\u00ae in the U.S. and received a total of $5,151(US$3,855). Revenue was recorded as follows: $4,483 (US$3,355) as licensing &hellip; Continue reading &quot;Crescita Reports Third Quarter 2020 Results&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/crescita-reports-third-quarter-2020-results\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2020-11-12T12:33:37+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mma.prnewswire.com\/media\/1332930\/Crescita_Therapeutics_Inc__Crescita_Reports_Third_Quarter_2020_R.jpg\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"15 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/crescita-reports-third-quarter-2020-results\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/crescita-reports-third-quarter-2020-results\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Crescita Reports Third Quarter 2020 Results\",\"datePublished\":\"2020-11-12T12:33:37+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/crescita-reports-third-quarter-2020-results\\\/\"},\"wordCount\":2991,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/crescita-reports-third-quarter-2020-results\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/1332930\\\/Crescita_Therapeutics_Inc__Crescita_Reports_Third_Quarter_2020_R.jpg\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/crescita-reports-third-quarter-2020-results\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/crescita-reports-third-quarter-2020-results\\\/\",\"name\":\"Crescita Reports Third Quarter 2020 Results - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/crescita-reports-third-quarter-2020-results\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/crescita-reports-third-quarter-2020-results\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/1332930\\\/Crescita_Therapeutics_Inc__Crescita_Reports_Third_Quarter_2020_R.jpg\",\"datePublished\":\"2020-11-12T12:33:37+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/crescita-reports-third-quarter-2020-results\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/crescita-reports-third-quarter-2020-results\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/crescita-reports-third-quarter-2020-results\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/1332930\\\/Crescita_Therapeutics_Inc__Crescita_Reports_Third_Quarter_2020_R.jpg\",\"contentUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/1332930\\\/Crescita_Therapeutics_Inc__Crescita_Reports_Third_Quarter_2020_R.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/crescita-reports-third-quarter-2020-results\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Crescita Reports Third Quarter 2020 Results\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Crescita Reports Third Quarter 2020 Results - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/crescita-reports-third-quarter-2020-results\/","og_locale":"en_US","og_type":"article","og_title":"Crescita Reports Third Quarter 2020 Results - Market Newsdesk","og_description":"PR Newswire Strong Ending Cash Balance of $13.9M LAVAL, QC, Nov. 12, 2020 \/CNW Telbec\/ Crescita Therapeutics Inc. (TSX: CTX) (OTC US: CRRTF) (&#8220;Crescita&#8221; or the &#8220;Company&#8221;), a growth-oriented, innovation-driven Canadian commercial dermatology company with in-house research &amp; development (&#8220;R&amp;D&#8221;) and manufacturing capabilities,\u00a0today reported its financial results for the third quarter ended September 30, 2020 (&#8220;Q3-F2020&#8221;). \u00a0All amounts presented are in thousands of Canadian dollars (&#8220;CAD&#8221;) unless otherwise noted. Financial Highlights \u00a0\u2013 Q3-F2020 vs. Q3-F2019 Revenue was $7,301 compared to $4,906, an increase of $2,395; In Q3-F2020, the Company amended its licensing agreement with commercial partner Taro Pharmaceuticals Inc. (&#8220;Taro&#8221;) for Pliaglis\u00ae in the U.S. and received a total of $5,151(US$3,855). Revenue was recorded as follows: $4,483 (US$3,355) as licensing &hellip; Continue reading \"Crescita Reports Third Quarter 2020 Results\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/crescita-reports-third-quarter-2020-results\/","og_site_name":"Market Newsdesk","article_published_time":"2020-11-12T12:33:37+00:00","og_image":[{"url":"https:\/\/mma.prnewswire.com\/media\/1332930\/Crescita_Therapeutics_Inc__Crescita_Reports_Third_Quarter_2020_R.jpg","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"15 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/crescita-reports-third-quarter-2020-results\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/crescita-reports-third-quarter-2020-results\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Crescita Reports Third Quarter 2020 Results","datePublished":"2020-11-12T12:33:37+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/crescita-reports-third-quarter-2020-results\/"},"wordCount":2991,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/crescita-reports-third-quarter-2020-results\/#primaryimage"},"thumbnailUrl":"https:\/\/mma.prnewswire.com\/media\/1332930\/Crescita_Therapeutics_Inc__Crescita_Reports_Third_Quarter_2020_R.jpg","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/crescita-reports-third-quarter-2020-results\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/crescita-reports-third-quarter-2020-results\/","name":"Crescita Reports Third Quarter 2020 Results - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/crescita-reports-third-quarter-2020-results\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/crescita-reports-third-quarter-2020-results\/#primaryimage"},"thumbnailUrl":"https:\/\/mma.prnewswire.com\/media\/1332930\/Crescita_Therapeutics_Inc__Crescita_Reports_Third_Quarter_2020_R.jpg","datePublished":"2020-11-12T12:33:37+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/crescita-reports-third-quarter-2020-results\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/crescita-reports-third-quarter-2020-results\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/crescita-reports-third-quarter-2020-results\/#primaryimage","url":"https:\/\/mma.prnewswire.com\/media\/1332930\/Crescita_Therapeutics_Inc__Crescita_Reports_Third_Quarter_2020_R.jpg","contentUrl":"https:\/\/mma.prnewswire.com\/media\/1332930\/Crescita_Therapeutics_Inc__Crescita_Reports_Third_Quarter_2020_R.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/crescita-reports-third-quarter-2020-results\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Crescita Reports Third Quarter 2020 Results"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/379483","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=379483"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/379483\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=379483"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=379483"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=379483"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}